48-50-JK Agri Genetics Ltd-Strand Life Sciences-Suven Life Sciences Limited
15 June 2010 | News
48
JK Agri Genetics Ltd
JK Agri Genetics Ltd.(JKAL), an erstwhile division of JK Tyre & Industries Ltd, clocked a total turnover of Rs 35 crores in 2009-2010. It was established in 1989 with its headquarters at Hyderabad, Andhra Pradesh. The company is concentrating on research and development, production, processing and marketing of hybrid seeds of sorghum, pearl millet, maize, cotton, rice, sunflower, tomato, okra and hot pepper. There are many hybrids marketed by the company. But fast moving hybrids are JK 99, JK DURGA, JK 666, JK INDRA, JK Varun (555), JK Chamundi. JK Agri Genetics got approval to launch its Bt cottonseeds in 2006 has sold 2.5 lakh packets. The company has been working on several genes for various traits like biotic and abiotic strains. It is also working on number of other crops for developing salinity/drought tolerant hybrids. It is building up its R&D as well as marker-assisted selection with novel traits with the help of biotechnology tools.
49
Strand Life Sciences
Life science informatics company Strand Life Sciences has registered a total revenue of Rs 35 crore in the fiscal year ended March 31, 2010. Strand leverages its core strengths and intellectual property in data mining, predictive modeling, bioinformatics, and computational chemistry to develop products and solutions for drug discovery. Five of the top ten pharmaceutical companies, three of the top six biotechnology companies, and numerous academic institutions across the globe, are part of Strand’s customer profile. Leveraging its unmatched interdisciplinary scientific expertise with its decision enabling technologies, Strand empowers biomedical and research scientists gain deep insights from raw data. Strand offers products and services in the areas of omics-based technologies, drug discovery, predictive systems modeling and knowledge management.
50
Suven Life Sciences Limited
Suven Life Sciences Limited, is a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders. The revenues for the year ended Mar’ 2010 from drug discovery and R&D services stood at Rs 33.5 crore compared to Rs 21.03 crore for the corresponding previous year. Including CRAMS business, revenue stood at Rs 129.8 crore.
Suven’s major thrust on innovative R&D in Drug Discovery continues with a total spending of Rs 34.16 crore (26 per cent on revenue) for the year ended Mar’ 2010 which lead to growth in R&D costs by 16 percent.
During the quarter there were major qualitative achievements in granting a product patent from USA (US 7,649,097) and a product patent (EP 1919896) from European Union for Suven’s drug discovery pipeline which consists of 12 molecules on 6 targets in CNS arena which are at various stages of preclinical and clinical development and these patents are valid until 2025 in addition to the clinical candidate SUVN-502 for Alzheimer’s and Schizophrenia.
JK Agri Genetics Ltd
| President | P S Dravid |
 |
| Business | Involved in R&D and marketing of agri biotech
products (Bt cotton seeds) |
|
| Start-up Year | 1989 | |
| Biotech Revenue | Rs 35 crore | |
| Address | 1-10-177, 4th floor, Varun Towers, Begumpet, Hyderabad
– 500016 |
|
| Tel | + 91-40-66316858 | |
| Fax | +91-40-27764943 |
|
| Website | www.jkseeds.net |
JK Agri Genetics Ltd.(JKAL), an erstwhile division of JK Tyre & Industries Ltd, clocked a total turnover of Rs 35 crores in 2009-2010. It was established in 1989 with its headquarters at Hyderabad, Andhra Pradesh. The company is concentrating on research and development, production, processing and marketing of hybrid seeds of sorghum, pearl millet, maize, cotton, rice, sunflower, tomato, okra and hot pepper. There are many hybrids marketed by the company. But fast moving hybrids are JK 99, JK DURGA, JK 666, JK INDRA, JK Varun (555), JK Chamundi. JK Agri Genetics got approval to launch its Bt cottonseeds in 2006 has sold 2.5 lakh packets. The company has been working on several genes for various traits like biotic and abiotic strains. It is also working on number of other crops for developing salinity/drought tolerant hybrids. It is building up its R&D as well as marker-assisted selection with novel traits with the help of biotechnology tools.
49
Strand Life Sciences
| Chairman & Ceo | Dr Vijay Chandru |
 |
| Business | Bioinformatics |
|
| Start-up Year | - | |
| Biotech Revenue | Rs 35 crore |
|
| Address | 5th Floor, Kirloskar Business Park, Bellary Road,
Hebbal, Bangalore-560024 |
|
| Tel | +91-80-40787263 | |
| Fax | +91-80-40787299 | |
| Website | www.strandls.com |
Life science informatics company Strand Life Sciences has registered a total revenue of Rs 35 crore in the fiscal year ended March 31, 2010. Strand leverages its core strengths and intellectual property in data mining, predictive modeling, bioinformatics, and computational chemistry to develop products and solutions for drug discovery. Five of the top ten pharmaceutical companies, three of the top six biotechnology companies, and numerous academic institutions across the globe, are part of Strand’s customer profile. Leveraging its unmatched interdisciplinary scientific expertise with its decision enabling technologies, Strand empowers biomedical and research scientists gain deep insights from raw data. Strand offers products and services in the areas of omics-based technologies, drug discovery, predictive systems modeling and knowledge management.
50
Suven Life Sciences Limited
| CEO | Venkat Jasti |
 |
| Business | Drug discovery |
|
| Start-up Year | 1989 | |
| Biotech Revenue | Rs 33.5 crore |
|
| Address | Serene Chambers, Road No. 5, Avenue - 7, Banjara
Hills, Hyderabad-500 034, Andhra Pradesh |
|
| Tel | +91- 40-23541142 | |
| Fax | +91-40-2354-1152 | |
| Website | www.suven.com |
Suven Life Sciences Limited, is a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders. The revenues for the year ended Mar’ 2010 from drug discovery and R&D services stood at Rs 33.5 crore compared to Rs 21.03 crore for the corresponding previous year. Including CRAMS business, revenue stood at Rs 129.8 crore.
Suven’s major thrust on innovative R&D in Drug Discovery continues with a total spending of Rs 34.16 crore (26 per cent on revenue) for the year ended Mar’ 2010 which lead to growth in R&D costs by 16 percent.
During the quarter there were major qualitative achievements in granting a product patent from USA (US 7,649,097) and a product patent (EP 1919896) from European Union for Suven’s drug discovery pipeline which consists of 12 molecules on 6 targets in CNS arena which are at various stages of preclinical and clinical development and these patents are valid until 2025 in addition to the clinical candidate SUVN-502 for Alzheimer’s and Schizophrenia.
